XPRIZE Healthspan" Semifinalists

Abe Yoando Pharmaceuticals, Inc. is pleased to announce that it has been selected as a TOP 40 (semi-finalist) team in XPRIZE Healthspan, the world's largest health and longevity competition.

XPRIZE Healthspan is an international competition to scientifically verify improvements in various functional changes associated with aging, and to achieve a healthy state equivalent to 10 to 20 years. More than 600 teams from 58 countries are participating to develop new approaches to age-related changes in muscle strength, cognitive function, and immune function.

THIS SEMIFINAL APPEARANCE WAS A RARE OPPORTUNITY FOR A PRIVATE JAPANESE COMPANY TO RECEIVE INTERNATIONAL RECOGNITION FOR ITS ORIGINAL RESEARCH INVOLVING NMN (NICOTINAMIDE MONONUCLEOTIDE) AND JOINT RESEARCH WITH DR. MOTONORI HAYANO, SPECIALLY-APPOINTED LECTURER AT KEIO UNIVERSITY AND ASSOCIATE PROFESSOR AT THE TOKYO UNIVERSITY OF SCIENCE'S FACULTY OF SCIENCE. DR. MOTONORI HAYANO, A SPECIALLY APPOINTED LECTURER AT KEIO UNIVERSITY AND ASSOCIATE PROFESSOR AT THE FACULTY OF SCIENCE, TOKYO UNIVERSITY OF SCIENCE, AND HIS JOINT RESEARCH EFFORTS HAVE RECEIVED INTERNATIONAL RECOGNITION.

We will conduct a one-year semi-final clinical study from August 1, 2025 to the end of March 2026, and submit the results of the study to the XPRIZE Healthspan Evaluation Committee. Based on the results of these clinical studies, the TOP 10 (finalists) will be selected in late 2026 and awarded a prize of US$1 million.

In addition, the teams selected as finalists will conduct a four-year final clinical trial beginning in October 2026. The results will be awarded a grand prize of up to US$81 million based on the number of years of life span extension.

‍

XPRIZE Healthspan Future Schedule

• May 12, 2025: Announcement of semi-finalists (40 teams / US$250,000 prize money)
• August 2025 - March 2026: Semi-final clinical trial conducted
• End of March 2026: Clinical study report submitted
• July-September 2026: Announcement of TOP 10 finalists (prize money US$1 million)
• October 2026 - December 2029: Final clinical trial conducted
• February 2030: Final report submitted
• December 2030: Grand Prix announced (up to US$81 million)

‍

Comments on the Award
Tomotaka Abe, Representative Director
From Japan, the country with the highest "longevity" in the world, we aim to realize "a society where people can enjoy life regardless of age". We will use this semifinalist opportunity to further advance our research and development, and will make every effort to deliver our research results to as many people as possible.

‍

Based on the results of our research to date, we will continue to take on the academic challenge of realizing a healthy and long-lived society, and will continue to build scientific evidence and bridge the gap to social implementation.

Special website and related information]
Details and progress of the XPRIZE Healthspan challenge are available on the special website as needed.
▶ https://corp.abeyoando.co.jp/x-prize

Press release

▶https://prtimes.jp/main/html/rd/p/000000085.000037884.html
November 2024 announcement release
▶https://prtimes.jp/main/html/rd/p/ 000000061.000037884.html

We look forward to your continued patronage of Abe Yoando Pharmaceuticals.

‍

‍

‍

Inquiry about this matter

Inquiry from this site:

https://corp.abeyoando.co.jp/support‍

Business hours: 10:00-17:00 weekdays (except Saturdays, Sundays, national holidays, year-end and New Year holidays, and summer vacation)

*We will reply in order after receiving your inquiry. Please note that it may take some time depending on holidays or the nature of the inquiry. Please understand this in advance.

*If you contact us on a regular holiday, we will reply on the next business day or later. ‍

‍

Official Line Account

Be the first to receive information on new products, events, and more. Click here to add a friend.

‍

‍

‍